Overview

Study to Assess the Efficacy and Safety of Adjunctive NBI-1065845 in Adults With Major Depressive Disorder (MDD)

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo used in addition to oral antidepressants in adults with MDD on improving symptoms of depression.
Phase:
Phase 2
Details
Lead Sponsor:
Neurocrine Biosciences